Exploring the potential role of PD-L2 in primary melanoma immunotherapy resistance: a hypothesis-driven dual-ligand framework
BackgroundThe treatment of melanoma has been significantly improved by immune checkpoint blockade (ICB); however, primary immune resistance, particularly in PD-L1-negative tumors and in selected treatment contexts, remains a critical efficacy bottlenec…